Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katrin Groebke Zbinden

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of Chemical Information and Modeling|July 17, 2025
Explainable Graph Neural Networks in Chemistry: Combining Attribution and Uncertainty QuantificationLeonid Komissarov, Nenad Manevski, Katrin Groebke Zbinden, et al.
Molecular Pharmaceutics|August 12, 2024
Actionable Predictions of Human Pharmacokinetics at the Drug Design StageLeonid Komissarov, Nenad Manevski, Katrin Groebke Zbinden, et al.
Journal of Chemical Information and Modeling|January 3, 2023
Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design StageRaya Stoyanova, Paul Maximilian Katzberger, Leonid Komissarov, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Design of selective phenylglycine amide tissue factor/factor VIIa inhibitorsKatrin Groebke Zbinden, David W Banner, Jean Ackermann, et al.
Bioorganic & Medicinal Chemistry|April 20, 2006
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensityKatrin Groebke Zbinden, David W Banner, Kurt Hilpert, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 AgonistsGuido Galley, Angélica Beurier, Guillaume Décoret, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2010
Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidateLilli Anselm, David W Banner, Jörg Benz, et al.
European Journal of Medicinal Chemistry|February 10, 2009
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hitKatrin Groebke Zbinden, Lilli Anselm, David W Banner, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2005
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitorsKatrin Groebke Zbinden, Ulrike Obst-Sander, Kurt Hilpert, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 2011
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activityFlorent G Revel, Jean-Luc Moreau, Raul R Gainetdinov, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Chemical Information and Modeling|July 17, 2025
Explainable Graph Neural Networks in Chemistry: Combining Attribution and Uncertainty QuantificationLeonid Komissarov, Nenad Manevski, Katrin Groebke Zbinden, et al.
Molecular Pharmaceutics|August 12, 2024
Actionable Predictions of Human Pharmacokinetics at the Drug Design StageLeonid Komissarov, Nenad Manevski, Katrin Groebke Zbinden, et al.
Journal of Chemical Information and Modeling|January 3, 2023
Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design StageRaya Stoyanova, Paul Maximilian Katzberger, Leonid Komissarov, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Design of selective phenylglycine amide tissue factor/factor VIIa inhibitorsKatrin Groebke Zbinden, David W Banner, Jean Ackermann, et al.
Bioorganic & Medicinal Chemistry|April 20, 2006
Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensityKatrin Groebke Zbinden, David W Banner, Kurt Hilpert, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery and Characterization of 2-Aminooxazolines as Highly Potent, Selective, and Orally Active TAAR1 AgonistsGuido Galley, Angélica Beurier, Guillaume Décoret, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2010
Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidateLilli Anselm, David W Banner, Jörg Benz, et al.
European Journal of Medicinal Chemistry|February 10, 2009
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hitKatrin Groebke Zbinden, Lilli Anselm, David W Banner, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2005
Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitorsKatrin Groebke Zbinden, Ulrike Obst-Sander, Kurt Hilpert, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 2011
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activityFlorent G Revel, Jean-Luc Moreau, Raul R Gainetdinov, et al.
Pageof 2